MENU
LYEL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Lyell Immunopharma (LYEL) Ownership - Who owns Lyell Immunopharma?
Lyell Immunopharma Inc is a clinical-stage cell therapy company... Show more
Profile
Industry
N/A
Address
201 Haskins Way
Phone
+1 650 695-0677
Employees
224
Web
https://www.lyell.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
169.7M
P/E Ratio
N/A
Total Cash
22.02M
Projected Growth
N/A
Total Debt
48.85M
Revenue
65K
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
1.49
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
LYEL
Capitalization
170M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
22M
Total Cash/Share
1.49
Total Debt
48.9M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
65K
ROE
N/A
Book Value
337M
P/B Ratio
0.50
Cash Flow
N/A
Earnings
-25
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
30K
Current Ratio
7.49
Current Revenue Per Employee
23.33
Dividends Per Share - Security
N/A
EBITDA
-204.02M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-59.52
Shares Held By Institutions
N/A
Shares Outstanding - Current
14.8M
Total Liabilities
93.3M
Total Volume MTD
N/A
Value
-1
Gain YTD
-10.469
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
201 Haskins Way
Phone
+1 650 695-0677
Employees
224
Web
https://www.lyell.com